Beijing Indoor Air Purifier Intervention Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02509000

Acronym

BIAPSY

Enrollment

Registered

2015-07-27

Start date

2013-12-31

Completion date

2014-11-30

Last updated

2015-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease

Brief summary

This study aimed to assess the impact of air filtration on indoor air quality and cardio-pulmonary health in residents living in high outdoor pollution settings in Beijing.

Interventions

OTHERair purifier

filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Global Initiative for Chronic Obstructive Lung Disease criteria (mild to moderate, GOLD stage I\ II; * severe to very severe, GOLD stage III\ IV) quit smoking for at least 1 year; * a ratio of pre-bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) equal to or less than 0.70 and an increase of FEV1 with the use of 400μg of albuterol of less than 12% of the pre-bronchodilator one; * no history of asthma or any other active lung disease. * Subjects were free from exacerbations for at least 6 weeks.

Exclusion criteria

* Patients with heart pacemaker, * heart failure with bundle-branch block, * recent myocardial infarction (in the last 12 weeks) and * anticoagulant therapy

Design outcomes

Primary

Measure	Time frame	Description
respiratory inflammation	4 weeks	analyzed EBC pH and inflammation biomarkers 8-isoprostane and nitrite and nitrate

Secondary

Measure	Time frame	Description
systemic inflammation	4 weeks	analyzed systemic inflammation biomarkers C-reaction Protein, Blood coagulation factor fibrinogen (Fib), Interleukin (IL) -8, -1β, -6, -10, -12p70 and tumor necrosis factor-α (TNF-α)
oxidative stress	4 weeks	analyzed systemic oxidative stress biomarker urinary 8-hydroxy-2-deoxyguanosine (8-OHdG)

Other

Measure	Time frame	Description
lung function	4 weeks	lung function test (FEV1, FEV1 %predicted, FEV1/FVC, 176 maximum midexpiratory flow (MMEF), MMEF %predicted) using an Aspirometer
autonomic function	4 weeks	twelve-hour ambulatory electrocardiogram (ECG) and blood pressure (BP) were monitored

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026